ArticleJournal of neurology2019
Motor, cognitive and behavioral differences in MDS PSP phenotypes.
Article in Journal of neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04691635 (MotOr, cogniTIVe and Imaging charactErization of Progressive Supranuclear Palsy Phenotypes), which is not on this map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
MotOr, cogniTIVe and Imaging charactErization of Progressive Supranuclear Palsy Phenotypes: a Longitudinal Prospective Study Looking for Biomarkers
Who cites it
37 citing papers in PubMed, 51 citations in OpenAlex.
- Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.Nature medicine · 2021Trial
- Longitudinal Cognitive Function in Progressive Supranuclear Palsy-A Review of the Evidence for Progression.Movement disorders clinical practice · 2026Review
- Interlocking pentagons task and visuospatial deficit in parkinsonian syndrome: a quantitative approach.Journal of neurology · 2026Article
- Dementia in Progressive Supranuclear Palsy: A Narrative Review.Neurology and therapy · 2026Review
- A Short Version of Carers' Quality of Life Questionnaire for Parkinsonism: Data from Progressive Supranuclear Palsy Network.Movement disorders clinical practice · 2026Article
- Differences in neuropsychological performance across clinical variants of progressive supranuclear palsy.Journal of the International Neuropsychological Society : JINS · 2025Article
- A smart tool for non expert clinicians for the dissemination of the MDS criteria for progressive supranuclear palsy.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Review
- Rapid Cognitive Deterioration in Progressive Supranuclear Palsy: A 1-Year Follow-Up Study.Movement disorders clinical practice · 2025Article
- Psychometric properties and clinical correlates of the Frontal Behaviour Inventory in progressive supranuclear palsy: data from the PSP-NET.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- Cognitive impairment in PSP compared with PD: assessment by clinical subtype and longitudinal change.BMJ neurology open · 2025Article
- Clinical prognostic factors in progressive supranuclear palsy: Implications for clinical trials.Journal of Parkinson's disease · 2024Article
- The contribution of white matter changes to clinical phenotype in progressive supranuclear palsy.Journal of neurology · 2024Article
- Longitudinal change of energy expenditure, body composition and dietary habits in Progressive Supranuclear Palsy patients.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Article
- Impaired sequence manipulation in non-demented patients with progressive supranuclear palsy.Brain and behavior · 2024Article
- Phenotypic Spectrum of Progressive Supranuclear Palsy: Clinical Study and Apolipoprotein E Effect.Journal of movement disorders · 2024Article
- Predicting Disability in Progressive Supranuclear Palsy Using Bedside Frontal-Lobe Signs.Movement disorders clinical practice · 2024Article
- Psychometric properties of the Caregiver's inventory neuropsychological diagnosis dementia (CINDD) in mild cognitive impairment and dementia.Journal of neural transmission (Vienna, Austria : 1996) · 2024Article
- Patterns of brain volume and metabolism predict clinical features in the progressive supranuclear palsy spectrum.Brain communications · 2024Article
- Investigating differences in young- and late-onset progressive supranuclear palsy.Journal of neurology · 2023Article
- Differentiating between common PSP phenotypes using structural MRI: a machine learning study.Journal of neurology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMovement Disorder Society (MDS) new diagnostic criteria for Progressive Supranuclear palsy (PSP) identifying different disease phenotypes were recently released. The aim of the present study is to report on the cognitive and behavioral features of the different phenotypes diagnosed according to the MDS criteria.
methodsForty-nine PSP patients underwent an extensive battery of clinical assessments. Differences between PSP subtypes were computed with χ
resultsHalf of the cohort presented Richardson's syndrome (46.9%), followed by PSP with parkinsonism and corticobasal syndrome (22.4% and 14.2%, respectively). Richardson's syndrome and PSP with corticobasal syndrome presented a similar burden of disease. The only cognitive testing differentiating the phenotypes were semantic fluency and ideomotor apraxia. The majority of our cohort was either affected by dementia or presented normal cognition. Richardson's syndrome presented the highest rate of dementia. The only marker of PSP non-Richardson's syndrome phenotype was better performance in visuo-spatial testing, implying worse visuo-spatial abilities in PSP Richardson's syndrome.
conclusionAvailable clinical assessments hardly capture differences between PSP phenotypes. The cognitive testing differentiating the PSP phenotypes were semantic fluency and ideomotor apraxia. In PSP, mild cognitive impairment likely represents an intermediate step from normal cognition to dementia. The only marker of PSP non-Richardson's syndrome phenotype was better performance in visuo-spatial testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.